Stock CLLS CELLECTIS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Company Cellectis S.A. Nasdaq

Equities

CLLS

US15117K1034

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:30:00 20/06/2024 BST 		5-day change 1st Jan Change
1.964 USD -2.53% Intraday chart for Cellectis S.A. -16.78% -36.23%
06-20 European Equities Traded in the US as American Depositary Receipts Move Higher in Thursday Trading MT
06-18 European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading MT

Business Summary

Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR-T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR-T cells for the treatment of cancer patients, and a platform for performing therapeutic genetic modifications in hematopoietic stem cells in a various diseases. Capitalizing on its 23 years of expertise in genome engineering, its TALEN® genome editing technology and its pioneering PulseAgile electroporation technology, Cellectis S.A. is developing innovative product candidates using the power of the immune system to treat diseases with unmet medical needs. As part of its commitment to the search for curative cancer therapies, Cellectis S.A. is developing UCART product candidates directed at the unmet medical needs of patients with certain types of cancer, including acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma. HEAL is a new platform focused on hematopoietic stem cells for the treatment of blood disorders, immune deficiencies, and lysosomal storage diseases.

Number of employees: 219

Sales per Business

EUR in Million2022Weight2023Weight Delta
Therapeutics
100.0 %
18 100.0 % 1 100.0 % -96.17%

Sales per region

EUR in Million2022Weight2023Weight Delta
France
100.0 %
18 100.0 % 1 100.0 % -96.17%

Managers

Managers TitleAgeSince
David Sourdive FOU
 Founder 57 19/12/99
André Choulika FOU
 Founder 59 19/12/99
Arthur Stril DFI
 Director of Finance/CFO 35 30/06/18
Mark Frattini CTO
 Chief Tech/Sci/R&D Officer 58 31/07/20
Stephan Reynier CMP
 Compliance Officer 55 31/03/11
Philippe Duchateau CTO
 Chief Tech/Sci/R&D Officer 61 31/12/00
Kyung Nam-Wortman HRO
 Human Resources Officer 54 15/11/20
Steve Doares PRN
 Corporate Officer/Principal - 20/07/20
Marie-Bleuenn Terrier LAW
 General Counsel 42 31/12/07

Members of the board

Members of the board TitleAgeSince
Jean-Pierre Garnier CHM
 Chairman 75 04/11/20
André Choulika FOU
 Founder 59 19/12/99
David Sourdive FOU
 Founder 57 19/12/99
Laurent Arthaud BRD
 Director/Board Member 61 27/10/11
Pierre Bastid BRD
 Director/Board Member 69 27/10/11
Axel-Sven Malkomes BRD
 Director/Board Member 57 27/06/22
Donald Bergstrom BRD
 Director/Board Member 52 27/06/22
Rainer Boehm BRD
 Director/Board Member 63 28/06/17
Cécile Chartier BRD
 Director/Board Member - 26/06/23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 71,810,231 71,751,201 ( 99.92 %) 0 99.92 %

Shareholders

NameEquities%Valuation
ASTRAZENECA PLC
22.30 %
16,000,000 22.30 % 42 M $
Bpifrance Participations SA /PRIVATE EQUITY/
8.186 %
5,873,247 8.186 % 15 M $
PFIZER, INC.
3.884 %
2,786,924 3.884 % 7 M $
Pierre Bastid
2.508 %
1,799,578 2.508 % 5 M $
Baillie Gifford & Co.
1.879 %
1,347,970 1.879 % 4 M $
CDC Croissance SA
1.449 %
1,039,906 1.449 % 3 M $
André Choulika
1.419 %
1,017,817 1.419 % 3 M $
David Sourdive
1.376 %
987,655 1.376 % 3 M $
Financière Arbevel SA
0.1761 %
126,342 0.1761 % 330 549 $
Saint Olive Gestion SNC
0.1185 %
85,000 0.1185 % 222 386 $
NameEquities%Valuation
Long Focus Capital Management LLC
6.254 %
4,487,293 6.254 % 12 M $
Capital Research & Management Co. (International Investors)
2.577 %
1,848,804 2.577 % 5 M $
Crédit Suisse Fund Management SA
2.005 %
1,438,255 2.005 % 4 M $
Baillie Gifford & Co.
1.153 %
827,248 1.153 % 2 M $
Principal Global Investors LLC
0.5917 %
424,533 0.5917 % 1 M $
Macquarie Investment Management Business Trust
0.3162 %
226,875 0.3162 % 614 831 $
KBC Asset Management NV
0.2278 %
163,447 0.2278 % 442 941 $
Oppenheimer & Co., Inc.
0.1866 %
133,890 0.1866 % 362 842 $
Jackson National Asset Management LLC
0.1627 %
116,754 0.1627 % 316 403 $
Morgan Stanley & Co. International Plc
0.1173 %
84,145 0.1173 % 228 033 $

Holdings

NameEquities%Valuation
CALYXTPAR
2.22%
 479,264 2.22% 6,930,157 $

Company contact information

Cellectis SA

8, rue de la Croix Jarry

75013, Paris

+33 1 81 69 16 00

http://www.cellectis.com
address Cellectis S.A.(CLLS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Cellectis S.A.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+35.14% 51.51B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-7.43% 39.03B
LONZA GROUP AG Stock Lonza Group AG
+35.88% 38.91B
CELLTRION, INC. Stock Celltrion, Inc.
-10.62% 26.68B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.63% 26.13B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-17.77% 19.91B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+40.52% 13.71B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.70% 12.38B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-3.41% 11.74B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALCLS Stock
  4. CLLS Stock
  5. Company Cellectis S.A.